ImmunoPrecise Antibodies : Report of Voting Results Submitted Pursuant to - Form 6-K
November 16, 2023 at 05:18 pm EST
Share
Report of Voting Results
Submitted Pursuant to
Section 11.3 of National Instrument 51-102 -Continuous Disclosure Obligations
In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of ImmunoPrecise Antibodies Ltd. (the "Corporation") held on November 9, 2023, via live webcast (the "Meeting"). Each of the matters is described in greater detail in the Corporation's management information circular dated October 16, 2023 (the "Circular").
(a)The number of directors was set at five. The following are the voting results on this matter:
FOR
% FOR
AGAINST
% AGAINST
Number of Directors
8,516,846
93.29%
612,909
6.71%
(b)In the Circular, management of the Corporation proposed five nominees for election as directors of the Corporation for the ensuing year or until their successors are duly elected or appointed. All five nominees were elected. The following are the voting results on this matter:
FOR
% FOR
WITHHELD
% WITHHELD
Jennifer L. Bath
6,985,276
94.46%
409,710
5.54%
Chris Buyse
7,325,144
99.06%
69,842
0.94%
Mitch Levine
7,324,705
99.05%
70,281
0.95%
Barry A. Springer
7,324,876
99.05%
70,110
0.95%
Dirk Witters
7,335,209
99.19%
59,777
0.81%
(c)Grant Thornton LLP was reappointed as the Corporation's auditors and the directors were authorized to fix the remuneration to be paid to the auditors. The following are the voting results on this matter:
ImmunoPrecise Antibodies Ltd. published this content on 16 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2023 22:16:07 UTC.
ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. It leverages systems biology, multiomics modelling and artificial intelligence systems to support its technologies in bioplatform-based antibody discovery. Its services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners to discover and develop novel biologics. It utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases. It offers services, such as immunogen design and manufacturing, B cell sorting incorporating its function-first B cell screening and sequencing, and the production and screening of custom, immune, and naive phage display libraries. It also operates LSA instrument platform, which is a provider of high-throughput large and small molecule screening and characterization solutions.